Last reviewed · How we verify
Midazolam demand
At a glance
| Generic name | Midazolam demand |
|---|---|
| Also known as | Versed |
| Sponsor | University of Pennsylvania |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Morphine, Midazolam and Dexmedetomidine in the Management of Acute Cardiogenic Pulmonary Edema, Safety and Efficacy (PHASE1)
- Anxiolysis for Laceration Repair in Children (PHASE3)
- A Single-centre Study of Entonox Versus Midazolam Sedation in Gastroscopy (PHASE4)
- Intermittent Boluses Versus Infusion of Propofol During Gastroscopy (NA)
- Modified TIPS Block for Total Knee Arthroplasty (PHASE4)
- Modeling and Application of Triple Drug Response Surface Models
- Propofol Patient-controlled Sedation for Endoscopic Retrograde Cholangiopancreatography (NA)
- Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Midazolam demand CI brief — competitive landscape report
- Midazolam demand updates RSS · CI watch RSS
- University of Pennsylvania portfolio CI